ArticleAnnals of hematology2020

KRD (carfilzomib and lenalidomide plus dexamethasone) for the treatment of relapsed or refractory multiple myeloma in the real-life: a retrospective survey in 123 patients.

Salvatore Palmieri et al.PubMed ↗Publisher ↗

No numbers read from the abstract.